ArticleCancer science2023

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.

Kohei Shitara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.